Precision BioSciences to Report Third Quarter Results on November 4, 2024
Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company, announced it will release its financial results for the third quarter of 2024 on November 4, 2024. The company utilizes its proprietary ARCUS® platform to develop in vivo gene editing therapies aimed at sophisticated gene edits. Along with the financial results, Precision BioSciences will also provide a business update.
Precision BioSciences (Nasdaq: DTIL), un'azienda nel settore dell'editing genico in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari per il terzo trimestre del 2024 il 4 novembre 2024. L'azienda utilizza la sua piattaforma proprietaria ARCUS® per sviluppare terapie di editing genico in vivo mirate a modifiche genetiche sofisticate. Insieme ai risultati finanziari, Precision BioSciences fornirà anche un aggiornamento aziendale.
Precision BioSciences (Nasdaq: DTIL), una empresa de edición genética en etapa clínica, anunció que publicará sus resultados financieros para el tercer trimestre de 2024 el 4 de noviembre de 2024. La empresa utiliza su plataforma propietaria ARCUS® para desarrollar terapias de edición genética in vivo dirigidas a ediciones genéticas sofisticadas. Junto con los resultados financieros, Precision BioSciences también proporcionará una actualización empresarial.
Precision BioSciences (Nasdaq: DTIL), 임상 단계의 유전자 편집 회사는 2024년 3분기 재무 결과를 2024년 11월 4일에 발표할 것이라고 발표했습니다. 이 회사는 독자적인 ARCUS® 플랫폼을 활용하여 정교한 유전자 편집을 목표로 하는 인비보 유전자 편집 치료제를 개발합니다. 재무 결과와 함께 Precision BioSciences는 비즈니스 업데이트도 제공할 예정입니다.
Precision BioSciences (Nasdaq: DTIL), une entreprise d'édition génétique en phase clinique, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre de 2024 le 4 novembre 2024. L'entreprise utilise sa plateforme propriétaire ARCUS® pour développer des thérapies d'édition génique in vivo visant des modifications génétiques sophistiquées. En plus des résultats financiers, Precision BioSciences fournira également une mise à jour sur l'activité de l'entreprise.
Precision BioSciences (Nasdaq: DTIL), ein Unternehmen für genediting im klinischen Stadium, gab bekannt, dass es seine Finanzzahlen für das dritte Quartal 2024 am 4. November 2024 veröffentlichen wird. Das Unternehmen nutzt seine proprietäre ARCUS®-Plattform, um in vivo Geneediting-Therapien zu entwickeln, die auf anspruchsvolle genetische Veränderungen abzielen. Neben den Finanzzahlen wird Precision BioSciences auch ein Geschäftsupdate bereitstellen.
- None.
- None.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029759701/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
Source: Precision BioSciences, Inc.
FAQ
When will Precision BioSciences report its third quarter 2024 results?
What is the stock symbol for Precision BioSciences?
What platform does Precision BioSciences use for gene editing?
